FarmavitaR+

1. Emerging Biosimilars Landscape
(Reports/Market Report)

Biosimilars: Key developments in the regulatory environment This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the ...

2. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of ...

3. The Top 10 Biosimilar Players
(Reports/Market Report)

... by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016. In the ...

4. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

US market offers the greatest biosimilar rewards With Japan poised to receive its first biosimilar and the US moving ever closer to the establishment of an approval pathway, the biosimilars market ...

5. Biosimilars
(Reports/Market Report)

Forecast Analysis The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. ...

6. Biosimilars-Regulatory Issues
(Reports/Product Report)

... a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European biosimilars market is significantly more advanced than the US, where plans for ...

7. Biosimilars: Benchmarking the key players
(Reports/Market Report)

With increasing regulatory clarity and high revenue potential, interest in biosimilars increases With increasing regulatory clarity and the expiries of key patents covering innovator biologics, ...

8. BioSimilars
(Biosimilars/Biosmimilars)

Biosimilars and the Centralised Procedure Dr Peter Richardson EMEA, Quality of Medicines Sector 071022s25-EN  ...

9. Biosimilars regulatory and development issues
(Reports/Market Report)

... passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars ...

10. Biosimilars - Strategic issues
(Reports/Market Report)

Strategic issues - Potential remains uncertain Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding ...

11. Growth Opportunities in Generics
(Reports/Market Report)

... in the sector. Opportunities for future success are also explored, including the potential offered by biosimilars and the increasing focus by governments on healthcare cost containment, enabling you to ...

12. The Future of Biosimilars
(Reports/Product Report)

The Future of Biosimilars: Key opportunities & emerging therapies Biotechnological products are continuing to exhibit substantial revenue gains, with the top 12 biologics registering sales ...

13. Biosimilars IP
(Biosimilars/Biosmimilars)

Biosimilars – inflated expectations? In October 2006, Senators Waxman, Schumer and Clinton introduced the “Access to Life-Saving Medicines Act” to the US Congress in an attempt to establish an abbreviated ...

14. Biosimilars
(Section)

Biosimilar pharmaceutical products